Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Knight Therapeutics Inc (OP: KHTRF )

3.750 +0.020 (+0.54%)
Streaming Delayed Price Updated: 12:28 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Knight Therapeutics Inc

Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
Via MarketBeat
Exposures Product Safety
Knight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin America
Knight Therapeutics Inc. (TSX: GUD) (OTC: KHTRF) 
Via Benzinga
Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer
Health Canada has approved Puma Biotechnology Inc's (NASDAQ: PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.